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Abstract
Background: Targeted therapy approaches have been successfully introduced into the treatment of several
cancers. The multikinase inhibitor Sorafenib has antitumor activity in solid tumors and its effects on acute
lymphoblastic leukemia (ALL) cells are still unclear.
Methods: ALL cell lines (SEM, RS4;11 and Jurkat) were treated with Sorafenib alone or in combination with
cytarabine, doxorubicin or RAD001. Cell count, apoptosis and necrosis rates, cell cycle distribution, protein
phosphorylation and metabolic activity were determined.
Results: Sorafenib inhibited the proliferation of ALL cells by cell cycle arrest accompanied by down-regulation of
CyclinD3 and CDK4. Furthermore, Sorafenib initiated apoptosis by cleavage of caspases 3, 7 and PARP. Apoptosis
and necrosis rates increased significantly with most pronounced effects after 96 h. Antiproliferative effects of
Sorafenib were associated with a decreased phosphorylation of Akt (Ser473 and Thr308), FoxO3A (Thr32) and 4EBP-
1 (Ser65 and Thr70) as early as 0.5 h after treatment. Synergistic effects were seen when Sorafenib was combined
with other cytotoxic drugs or a mTOR inhibitor emphasizing the Sorafenib effect.
Conclusion: Sorafenib displays significant antileukemic activity in vitro by inducing cell cycle arrest and apoptosis.
Furthermore, it influences PI3K/Akt/mTOR signaling in ALL cells.
Background
Acute lymphoblastic leukemias (ALL) can occur during
childhood and more rarely during adulthood. Especially
adult patients still have a grave prognosis following con-
ventional chemotherapies despite progress in the treat-
ment during recent years. Therefore, risk adapted therapy
approaches have been developed including allogenic stem
cell transplantation as well as targeted therapies. In parti-
cular, CD20 antibody treatment has been successfully
introduced in B-ALL [1]. In addition, signal transduction
inhibitors such as the tyrosine kinase inhibitor Imatinib
have been used in BCR-ABL positive ALL patients leading
to improved response rates [2,3]. Investigation of further
targeted therapy approaches e.g. inhibition of signaling
pathways is aiming at inhibiting other dysregulated tyro-
sine kinases or transcription factors.
Sorafenib is a multikinase inhibitor targeting Raf ser-
ine/threonine kinases as well as different receptor tyro-
sine kinases including c-Kit, FLT-3, vascular endothelial
growth factor receptor (VEGFR) and platelet-derived
growth factor receptor (PDGFR) [4,5]. Sorafenib has
previously been shown to induce apoptosis and necrosis
in various types of cancer such as renal cell carcinoma,
breast cancer, lung cancer, colon cancer, chronic myelo-
genous leukemia (CML), chronic lymphocytic leukemia
(CLL) and acute myeloid leukemia (AML) [6-8]. Cell
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viously for their response to Sorafenib. It was shown
that Sorafenib inhibits cell growth of renal cell carci-
noma cells, pancreatic tumor cells, colon cancer, breast
tumor cells and melanoma tumor cells [9,6]. Sorafenib
has recently been approved for the clinical treatment of
hepatocellular carcinoma and renal cell carcinoma [10].
Furthermore it is under clinical investigation in FLT3
positive acute myeloid leukemia (AML) patients [8,11].
In the present study we investigated the effect of the
multikinase inhibitor Sorafenib on B- and T-ALL cells.
Our results demonstrate that Sorafenib inhibits prolif-
eration and induces apoptosis as well as necrosis in ALL
cells. In addition, we could demonstrate the inhibitory
effect of Sorafenib on the PI3K/Akt pathway.
Methods
Cell lines
ALL cell lines with different cytogenetics and pheno-
types were used. The human ALL cell lines SEM,
RS4;11 (both B-ALL) and Jurkat (T-ALL) were pur-
chased from DSMZ (Braunschweig, Germany) and cul-
tured according to manufacturer’sp r o t o c o l .T h em e d i a
were supplemented with 10% heat-inactivated fetal
bovine serum (PAA, Pasching, Austria) and 1% penicillin
and streptomycin (Biochrom AG, Berlin, Germany). All
cells were grown in a 37°C and 5% CO2 humidified
atmosphere-incubator.
Inhibitors and cytostatics
Sorafenib was a kind gift from Bayer Healthcare (Leverku-
sen, Germany). The mTOR inhibitor RAD001 was kindly
provided from Novartis (Basel, Switzerland). Inhibitors
were dissolved in dimethyl sulfoxide (DMSO) and stored
as stock solution at -20°C. Cytarabine and doxorubicin
were purchased from cell pharm GmbH (Bad Vilbel,
Germany) and dissolved in 5% NaCl (B. Braun Melsungen
AG, Melsungen, Germany).
For experimental use drugs were prepared freshly
from stock solution. Control cells were cultured in their
medium containing the same concentration of DMSO
as the experimental treated cells. Drug concentrations
were chosen in accordance with serum concentration
that can be achieved in clinical settings.
Inhibition experiments and drug combination studies
Cells (5 × 10
5/well) were seeded in 24 well plates (Nunc,
Langenselbold, Germany) and treated with inhibitors for
up to 96 h. Sorafenib was investigated as single drug
and in combination with conventional cytostatics cytara-
bine and doxorubicin. In addition, the mTOR inhibitor
RAD001 was combined with Sorafenib. Cells were incu-
bated with sub -IC50 concentration of cytostatics cytara-
bine (250 nM), doxorubicin (25 nM) or RAD001 (1 nM
and 10 nM) and with Sorafenib (0.73 μMa n d7 . 3μM)
alone and in combination. Sub -IC50 concentrations of
cytostatics were used to detect synergistics effects easier.
IC-50 values of each drug had been determined in pre-
vious experiments. Inhibitors were added once at the
time of cell seeding. Samples of cells were harvested
after 0.5, 2.5, 4.0, 24, 48, 72 and 96 h and used for
analyses.
Analyses of apoptosis and necrosis
Apoptosis and necrosis were determined using Annexin
V FITC (BD Biosciences, Heidelberg, Germany) and
propidium iodide (PI) (Sigma Aldrich, St. Louis, USA)
labeling technique and flow cytometry analyses. Briefly,
5×1 0
5 cells were harvested and washed twice (180 g,
10 min, 4°C) with PBS at indicated points in time. Each
cell pellet was resuspended in 100 μlo fb i n d i n gb u f f e r
(1×) and 5 μl Annexin V FITC were added. After an
incubation time of 10 min at room temperature, addi-
tional 400 μl of binding buffer were added for a final
volume of 500 μl. Cells were stained with PI (0.6 μg/ml)
immediately before measurement. Unstained and single
stained controls were included in each experiment. Flow
cytometry analyses were performed using FACSCalibur
(Becton and Dickinson, Heidelberg, Germany) and data
thus obtained were analysed with CellQuest software
(Becton and Dickinson, Heidelberg, Germany).
Proliferation studies
Cell counts were determined using the trypan blue stain-
ing. Metabolic activity was determined using tetrazolium
compound (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate) [WST-1, Roche,
Mannheim, Germany] according to the manufacturers
protocol. In brief, cells (5 × 10
4/well) were seeded in 96
well plates in triplicates and incubated with 15 μlW S T - 1
for 4 h. The assay is based on the reduction of tetrazo-
lium salt WST-1 to soluble formazan by mitochondrial
dehydrogenases of the cells. The amount of formazan dye
directly correlates to the number of metabolically active
cells and was detected by the absorbance at 450 nm and
a reference wavelength at 620 nm by an ELISA Reader
(Anthos, Krefeld, Germany). The absorbance of culture
medium plus WST-1 in the absence of cells was used as
background control.
Cell cycle analysis
After treatment SEM and Jurkat cells were harvested
and washed twice in PBS. Cells were fixed with 70%
ethanol and incubated with 1 mg/ml Ribonuclease A
(Sigma-Aldrich, St. Louis, USA) for 30 min at 37°C.
Subsequently, cells were washed twice in PBS and
stained with PI. DNA content was analyzed by flow
cytometry on a FACSCalibur Cytometer (Becton and
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formed using CellQuest software (Becton and Dickinson,
Heidelberg, Germany).
Western blot
For protein extraction 1 × 10
6 cells were washed twice
in PBS and lysed with RIPA buffer (50 mM Tris HCl
pH 7.4; 150 mM NaCl; 0.1% SDS and 1% NP40) includ-
ing protease and phosphatase inhibitors (Roche Applied
Science, Mannheim, Germany). Samples were incubated
for 20 min at 4°C and frozen at -20°C. Cell extracts
were thawed and centrifuged at 12000 g for 10 min at
4°C. Total protein concentration of supernatants was
determined using Bio-Rad Protein Assay (Bio-Rad,
München, Germany).
Equal amounts of protein samples were separated by
SDS-polyacrylamid gel (8% or 15%) electrophoresis and
transfered onto a PVDF membrane (Amersham Bios-
ciences, Buckinghamshire, UK). Membranes were
blocked in 5% milk or 5% BSA and incubated at 4°C
overnight with the following polyclonal antibodies: rab-
bit anti-cleaved caspase 3, rabbit anti-caspase 3, rabbit
anti-cleaved PARP, rabbit anti-cleaved caspase 7, rabbit
anti-caspase 7, rabbit anti-pErk1/2 (Thr202/Tyr204),
rabbit anti-Erk, rabbit anti-pAktThr308, rabbit anti-
pAktSer473, rabbit anti-Akt, rabbit anti-p15
INKB,r a b b i t
anti-p27
KIP1, mouse anti-CDK4, mouse anti-CyclinD3
(all Cell Signaling Frankfurt/Main, Germany), rabbit
anti-pFoxO3AThr32 and rabbit anti-FoxO3A (both
Upstate, Temecula, USA). Blots were incubated with
mouse anti-a-tubulin antibody or mouse anti-GAPDH
(both Invitrogen, Carlsbad, USA) as loading control.
Specific horseradish peroxidase-conjugated secondary
antibodies (anti-mouse or anti-rabbit) were used. Blots
were re-probed using Restore Plus Western Blot strip-
ping buffer (Pierce, Rockford, USA). Signals were
detected with ECL Plus reagent (Amersham Bios-
ciences; Buckinghamshire, UK) and a CCD camera
(Kodak Digital Sience Image Station 440CF, Rochester,
USA).
Statistical analysis
Experiments were conducted in triplicates and results
within each experiment were described using mean ±
standard deviation (SD). Significant effects (*) between
treatment groups, or between treatment groups and
control was accomplished by using the two-sample Stu-
dent’s t-test. For more than two independent samples,
the total significance level a = 0.05 was Bonferroni
adjusted for each pairwise test (aadj). All p-values
resulted from two-sided tests. The nature of interaction
between Sorafenib and other drugs was characterized
using Bliss additivism model [12-14].
Results
Sorafenib inhibits proliferation and induces apoptosis in
ALL cells
The influence of the multikinase inhibitor Sorafenib on
proliferation in ALL cell lines SEM, RS4;11 and Jurkat
was analyzed. Cells were incubated with two different
concentrations of Sorafenib (0.73 μMa n d7 . 3μM).
Results are summarized in Figure 1. Cell proliferation of
all investigated ALL cell lines was significantly inhibited
at a Sorafenib concentration of 7.3 μM. Proliferation
inhibition was seen as early as 24 h after first exposure.
The most pronounced effects were achieved at 96 h.
Treatment with 0.73 μM Sorafenib also inhibited the
proliferation in SEM cells, but not in RS4;11 and Jurkat
cells.
Sorafenib induced apoptosis and necrosis in ALL cells.
Highest mean apoptosis and necrosis rates with 7.3 μM
Sorafenib were 30.8%, 26.8%, 43.4% and 72.9%, 70.4%,
60.5% for SEM, RS4;11 and Jurkat, respectively. Analyses
for apoptosis and necrosis using Annexin FITC and Pro-
pidiumiodid stainig are presented in Figure 2A. Dot
plots are shown for SEM cells after Sorafenib exposure
at 24 h and 48 h.
We then investigated the effects of Sorafenib on apop-
tosis induction in SEM and Jurkat cells in more detail.
Treatment with Sorafenib induced apoptosis by cleavage
of caspases 3, 7 and PARP that was observed already
24 h after treatment with 7.3 μM Sorafenib. Results are
displayed in Figure 2.
Sorafenib induces cell cycle arrest
Sorafenib inhibited cell cycle progression therby leading
to a decreased cell proliferation. Cell cycle analysis
exhibited an increase of SEM and Jurkat cells in G0/G1
phase which was accompanied by a reduction of cells in
S- and M phase from 20.4%, 32.2% (DMSO) to 10.1%,
31.4% (0.73 μM) and 6.8%, 17.1% (7.3 μM) at 96 h,
respectively. Cell cycle analyses of SEM cells are dis-
played in Figure 3A. Results for both cell lines are sum-
marized in table 1. In addition, G0/G1 arrest was
confirmed by western blot analysis in SEM and Jurkat
cells (Figure 3B). Downregulation of CDK4 and
CyclinD3 were detected 24 h after Sorafenib treatment
at 7.3 μM. The protein levels of the CDK4 inhibitor
p15
INK4 increases, but in contrast the protein expression
of CDK2 inhibitor p27
KIP1 decrease in SEM cells,
whereas Sorafenib did not affected the CDK inhibitors
in Jurkat cells.
Furthermore, we evaluated metabolic activity by mea-
suring mitochondrial dehydrogenases activity in cells
using WST-1 assay. Incubating the cells with 7.3 μM
Sorafenib resulted in a significant decrease of mitochon-
drial dehydrogenases activity in SEM, RS4;11 and Jurkat
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nificant inhibition of metabolic activity in SEM cells but
not in RS4;11 and Jurkat. Results of WST-1 assay after
treatment with Sorafenib in SEM, RS4;11 and Jurkat
after 48 h are shown in Figure 3C.
Sorafenib inhibits Erk, mTOR and Akt
Based on the observation that Sorafenib inhibits prolif-
eration, we performed western blot analyses for Erk,
4-EBP-1, Akt and FoxO3A to characterize the effects of
Sorafenib on Raf/Mek/Erk pathway and PI3K/Akt/
mTOR pathway (Figure 4). Sorafenib induced a decrease
in phosphorylated Erk1/2 (Thr202 and Tyr204) with 0.73
μM and 7.3 μM at 4 h and 24 h in SEM cells (Figure 4A).
To investigate further the Sorafenib inhibition on the
PI3K/Akt pathway, we examined downstream signaling
of mTOR by analyzing the phosphorylation status of
4EBP-1. As shown in Figure 4B, treatment of 0.73 μM
and 7.3 μM resulted in a suppression of p-4EBP-1 on
both phosphorylation sites (Ser65 and Thr70) in SEM
cells. In Jurkat cells mTOR signaling was exhibited
by reduced phosphorylation of p-4EBP-1 on Ser65
a n dn o tm o d u l a t e do nT h r 7 0w i t h7 . 3μM Sorafenib.
Furthermore, incubation with Sorafenib for 0.5 h led to
decreased levels of pAkt at both phosphorylation sites in
SEM, RS4;11 and Jurkat cells. In line, pFoxO3AThr32
decreased. Whereas the inhibition of Akt were pro-
nounced in SEM and RS4;11, they were less explicit in
Jurkat cells (Figure 4C).
Sorafenib acts synergistically in combination with
cytostatics
In order to detect and classify the effects of Sorafenib in
combination with other cytostatics, a series of experi-
ments were performed. Sorafenib (0.73 μMa n d7 . 3μM)
was used in a total of eight simultaneous combinations
with either 250 nM cytarabine, 12.5 nM doxorubicin,
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Figure 1 Treatment with Sorafenib inhibits cell proliferation and induces apoptosis. SEM, RS4;11 and Jurkat cells were exposed to the
indicated concentrations of Sorafenib. The proliferation of SEM, RS4;11 and Jurkat are significantly inhibited, with most pronounced effects at
96 h. Apoptotic and necrotic cells were analyzed using Annexin V/PI staining followed by flow cytometry. Apoptosis and necrosis rates increased
in B- and T-ALL cell lines following Sorafenib treatment. Results are displayed as mean +/- SD of three independent experiments.
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Page 4 of 11effects started to become apparent from time point 72 h
( s e eF i g u r e .1 ) ,am o r ed e t a i l e da n a l y s i sf o rS E Ma t7 2h
is presented (Figure 5). Inhibition of cell proliferation of
each of the combinations (Sorafenib + 2
nd Drug) com-
pared to DMSO control reached statistical significance.
Inhibition effects of single agent treatments vs. DMSO
control, as well as combinations vs. single agents were
detected, but did not reach statistical significance.
In addition, inhibitory treatment effects of all eight
combinations on proliferation were classified to become
Annexin V FITC
DMSO
7.3 µM
Cleaved Caspase 3
Caspase 3
GAPDH
Cleaved PARP 
GAPDH
Cleaved Caspase 7
Full Length Caspase 7
GAPDH
7.1 % 6.0 %
32.4 %
27.3 %
6.5 %
14.4 %
18.1 %
A
B
7.6 %
24 h 48 h
Figure 2 Sorafenib induces apoptosis via cleavage of caspases. (A) Apoptotic (Annexin V FITC
+ and Propidium iodide
-) and necrotic cells
(Annexin V FITC
+ and Propidium iodide
+) were detected by flow cytometry analysis at 24 h and 48 h following Sorafenib treatment. Results are
displayed for SEM cells treated with DMSO or 7.3 μM Sorafenib. (B) Cells were treated as described in Figure 1. Total cell lysates (25 μg) were
analyzed by Western blot to detect the cleavage of Caspase 3, 7 and PARP. GAPDH was used as control for equal loading.
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Page 5 of 11“Bliss synergistic” ones with increasing concentrations of
Sorafenib (the Bliss analyses are summarized in the
additional file 1). This emphasizes a percentage increase
in maximal inhibition and is above the expected strictly
“Bliss additive” in nature effect, attributed just to the
impact of Sorafenib-co-treatment with cytostatics.
Further treatment effects on proliferation, apoptosis and
necrosis are noticeable, but not verifiable, reflecting the
feature of synergistic effects that mixture toxicities are
detectable at low, statistically non-significantly acting
concentrations of the single compounds.
Discussion
Targeted therapy of leukemias with specific inhibitors has
been shown to be effective and clinically well tolerated. In
the present study, we have investigated the effect of the
multikinase inhibitor Sorafenib in regards to influence on
proliferation, apoptosis and necrosis in B- and T-
lymphoblastic cells. Significant antiproliferative effects of
Sorafenib were observed with 7.3 μM (a clinically achiev-
able serum concentration) in all investigated cell lines.
Inhibition of proliferation was also inducible with lower
concentration (0.73 μM) in SEM cells. We could further
demonstrate that Sorafenib induces caspase activation by
cleavage of caspases 3 and 7 which results in cleavage of
the nuclear protein PARP. Sorafenib has been previously
shown to activate apoptosis and necrosis in various types
of cancer [6,7,15-17]. In AML it was shown that treat-
ment with Sorafenib activates the intrinsic apoptotic
pathway by up-regulation of Bim associated with an
G0/G1 M S
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Figure 3 Sorafenib inhibits cell cycle progression and metabolic activity. (A) Effects of Sorafenib on cell cycle distribution was determined by
DNA staining with Propidium iodide and flow cytometry in SEM cell line. Sorafenib induces a reduction of cells in M and S phases. (B) Cell cycle arrest
was confirmed by western blot 24 h after Sorafenib treatment in SEM and Jurkat cells. Membranes were incubated with the indicated antibodies
against cell cycle regulator proteins. GAPDH was used as control for equal loading. Reduction of CDK4 and Cyclin D3 were detected at 7.3 μM
Sorafenib in both cell lines. (C) SEM, RS4;11 and Jurkat cells were treated with the indicated concentration of Sorafenib for 48 h and metabolic activity
were analyzed using WST-1 Assay. Metabolic activity measured by formazan dye is shown as a difference in absorbance measured at 450 nm and 620
nm (reference) wavelengths, respectively. Treatment with 7.3 μM of Sorafenib induced a statistically significant (*aadj = 0.017) inhibition of proliferation
in SEM, RS4;11 and Jurkat cells, 0.73 μM Sorafenib in SEM cells as well. Results are displayed as mean +/- SD of three independent experiments.
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Page 6 of 11increase of Bad, Bax and Bak proteins [8]. Further, it was
demonstrated that Sorafenib-induced apoptosis resulted
in down-regulation of Mcl-1, caspase activation and cyto-
chrome c release in different cancer cells [6,18].
Whereas the effects of Sorafenib on Raf, Mek, Erk
inhibition are well established in a variety of different
cancers, its effects on the Akt signaling pathway is less
clear. Since we and other have shown earlier, that the
Akt pathway is activated in ALL cells, we aimed to
detect Sorafenib effects on the PI3K/Akt/mTOR path-
way. We demonstrated an inactivation of Akt after treat-
ment with Sorafenib in SEM and RS4;11 achieving a
complete disappearance of phosphorylated Akt. In Jur-
kat cells, that harbor a PTEN deletion, a marked
decrease of pAkt levels (pAktSer473 and pAktThr308)
occurred. In previous studies with several cancers, Sora-
fenib has not been shown to inhibit Akt phosphorylation
[10,19,20]. Furthermore, it was demonstrated with bio-
chemical assays, that Sorafenib is not a direct inhibitor
of Akt [9]. In contrast, different studies indicated that
Sorafenib induced an inhibition of STAT3 (phosphory-
lated signaltransducers and activators of transcription 3)
that were associated with decreased levels of pAkt in
glioblastoma cells, pancreatic cancer cell lines and neu-
roblastoma cells [16,21,22]. Moreover, we analyzed
mTOR kinase activity by analyzing the phosphorylation
sites of 4EBP-1. In SEM and Jurkat cells reduced levels
of p-4EBP-1 (Ser65 and Thr70) were detected with 7.3
μM Sorafenib after 0.5 h treatment. In addition, we
showed a decrease of phosphorylation of transcription
factor FoxO3A as a result of an inhibition of Akt.
Dephosphorylation of Akt leads to a relocalization of
FoxO3A from cytoplasm into the nucleus and acts as
transcription factor [23-25]. FoxO3A transcribes proa-
poptotic genes and cell cycle inhibitors such as Bim-1,
Bcl-6, Trail, p21Cip1, p27Kip1 and GADD45 which pro-
teins block cell cycle progression or induce apoptosis,
respectively [26,27]. In our study, we showed that anti-
proliferative effects of Sorafenib are caused by cell cycle
arrest as well as apoptosis. G0/G1 arrest was associated
with a decrease of CyclinD3 and CDK4 as well as an
increase of p15
INKB in SEM and Jurkat Sorafenib (0,73
μM) treated cells. In contrast, protein levels of CDK2
inhibitor p27
Kip1 were lower than in untreated SEM
cells, indicating that CDK2 inhibition were affected not
only by FoxO3A transcription factors. In comparison to
SEM cells, protein expression of p27
Kip1 is lower and
not affected in Jurkat cells.
Our results indicate that Sorafenib influences not only
the Raf/Mek/Erk pathway but also the PI3K/Akt/mTOR
signaling pathway. Ulivi P et al. showed that Sorafenib
exhibit a strong anti-proliferative effect independently of
Ras/Raf/Mek/Erk [21]. The mechanism by which Sorafe-
nib inhibits Akt phosphorylation remains uncertain.
Decreased levels of pAkt might be caused by inhibiting
different upstream tyrosine kinases, as Sorafenib has
also a potent activity against VEGFR, c-Kit, c-Raf and B-
Raf [5]. Expression of VEGFR-2 has been demonstrated
in haematopoetic stem cells. After ligand binding of
VEGFR-2 and following autophosphorylation, the Ras/
Raf/Mek/Erk pathway and the PI3K/Akt signaling cas-
cade are activated [28]. In this context, we presume a
cross-talk between both pathways that provide Akt inhi-
bition after Sorafenib treatment in ALL cells. Recent
studies described an interaction between MAPK and
mTOR pathway [29,30]. These findings support our
hypothesis that Sorafenib-induced inhibition of PI3K/
Akt/mTOR as a result of blocking upstream several tyr-
osine kinases as well as Ras/Raf/Erk pathway.
Further, it is known that Sorafenib inhibits FMS-like
tyrosine kinase 3 (FLT3). This receptor tyrosine kinase
is mainly expressed in early myeloid and lymphoid
progenitor cells and activates PI3K and Ras signal-
transduction cascades [31]. Internal tandem duplica-
tion insertions in the juxtamembrane domain of FLT3
(FLT3-ITD) leads to constitutive activation of this
receptor. FLT3-ITD are common in AML (25%)
whereas this mutation occurs much less frequently in
ALL (<1%) [32]. Additionally, it has been reported that
mixed-lineage leukemia gene (MLL) rearrangement
and hyperdiploid patients offer point mutations in the
activation loop in the tyrosine kinase domain of FLT3
[33]. This mutation results in ligand-independent
receptor dimerization, phosphorylation and constitutive
activation of downstream signalling pathways and is
more frequent in ALL (5-22%) [32,34]. SEM and
RS4;11 are precursor B-ALL cell lines and carry the t
(4;11) MLL-AF4 fusion protein. However, both cell
lines are negative for FLT3-ITD.
Table 1 Results of cell cycle analyses in SEM and Jurkat
cells
SEM Jurkat
Time Phase DMSO 0.73
μM
7.30
μM
DMSO 0.73
μM
7.30
μM
24 h G0/G1 84.6% 87.2% 85.4% 70.4% 72.8% 61.9%
S 8.3% 4.2% 8.4% 6.8% 11.7% 18.2%
M 7.1% 8.6% 7.2% 22.8% 15.5% 19.9%
48 h G0/G1 79.6% 93.5% 86.3% 72.2% 57.3% 83.1%
S 9.9% 2.3% 3.8% 13.3% 14.7% 6.7%
M 10.5% 4.2% 9.9% 14.5% 28.0 10.2%
72 h G0/G1 84.0% 95.9% 91.6% 75.2% 69.3% 83.0%
S 8.7% 2.4% 6.2% 14.0% 18.3% 10.5%
M 7.3% 1.7% 2.2% 10.8% 12.4% 6.5%
96 h G0/G1 79.6% 89.9% 93.2% 67.8% 68.6% 82.9%
S 10.7% 4.2% 3.3% 13.5% 17.0% 11.6%
M 9.7% 5.9% 3.5% 18.7% 1.4% 5.5%
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tion of cytostatic drugs is commonly a reasonable
approach. Successful combination therapy might enhance
the impact of inhibitors, allowing lower doses of cyto-
static drugs and thereby reducing side effects. Different
studies in patients with melanoma, hepatocellular carci-
noma or non-small-cell lung cancer suggest that Sorafe-
nib has the potential to be combined with a variety of
cytotoxic drugs and targeted agents [35-37]. Here, we
treated cells with 0.73 μMo r7 . 3μM Sorafenib in combi-
nation with sub-IC50 concentrations of cytarabine, dox-
orubicin and the mTOR inhibitor RAD001. Our studies
demonstrate that the in vitro effect of co-treatment with
Sorafenib and cytostatics is “Bliss synergistic” in B-ALL
cells regarding proliferation, apoptosis and necrosis as
well. These results indicate that simultaneous application
of Sorafenib with the tested conventional cytotoxic drugs
might lead to synergistic impact, exceeding the expected
pure “additive” effect of individual compounds with inde-
pendent action. The results obtained indicate that the
effects of the mixtures of Sorafenib and cytostatics can be
studied experimentally, even at low concentrations of the
single components.
We suppose that pre-treatment with cytarabine might
potentate the in vitro effect of Sorafenib and maximize
apoptosis and necrosis rates. Integration of cytarabine is
restricted and occurs mainly during the S-phase of cells.
In our study, we demonstrated that Sorafenib induced
cell cycle arrest by decreasing the proportion of cells in
the S and M phase hindering the efficacy of cytarabine.
Auclair et al. reported that Sorafenib induces G0/G1
arrest in AML cells [7]. Levis et al.e l u c i d a t e dt h a tp r e -
treatment with chemotherapy induce synergistic interac-
tions, whereas treatment of cells with the FLT3 inhibitor
pAktSer473
Akt
pFoxO3AThr32
Loading control
FoxO3A
pAktThr308
DMSO         0.73 µM       7.3 µM
J 1 1 ; 4 S R                                                                                   M E S urkat
DMSO    0.73 µM    7.3 µM
0.5   2   4    0.5  2  4    0.5  2   4 0.5  2   4  24  0.5  2   4 24 0.5  2  4   24 
DMSO    0.73 µM    7.3 µM
0.5   2   4    0.5  2  4    0.5  2   4
p-4EBP-1 
Thr70
p-4EBP-1 
Ser65
4EBP-1
GAPDH
0.5 h 4.0 h
SEM 
DMSO  0.73  7.3   DMSO 0.73  7.3 
Jurkat
C
B
time (h)
DMSO  0.73  7.3  DMSO  0.73  7.3 
0.5 h 4.0 h
GAPDH
pERK1 Thr202
pERK2 Tyr204
ERK1/2 
DMSO  0.73  7.3 DMSO  0.73  7.3 
4 h 24.0 h
SEM  A
Figure 4 Treatment with Sorafenib inhibits the Ras/Raf/Erk and PI3K/Akt/mTOR pathway. Western blot experiments for serveral target
proteins are displayed. ALL cell lines were treated with Sorafenib for the indicated time periods. Total cell lysates (25 μg) were separated by
electrophoresis on an 8% SDS-Page gel. Membranes were incubated with the indicated antibodies against Erk1/2 and PI3K/AKT/mTOR signaling
pathway-related proteins. GAPDH was used as control for equal loading. (A) Sorafenib induced down-regulation of pErk1/2 (Thr202 and Thr204)
in SEM cells at 4 h and 24 h after treatment. (B) Inhibition of mTOR was detectable as a decrease of p-4EBP-1 (Thr70 and Ser65) protein in B-
and T-ALL cells with 7.3 μM Sorafenib. (C) Sorafenib down-regulated the phosphorylation of Akt (Thr308 and Ser473) and reduced the
phosphorylation of FoxO3A (Thr32) in SEM, RS4;11 and Jurkat cells.
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Page 8 of 11CEP-701 followed by cytarabine administration results
in antagonistic effect in FLT3/ITD expressing leukemia
cell lines [38]. In contrast, Zhang et al. demonstrated
that combination of Sorafenib with cytarabine synergisti-
cally inhibits in vitro growth in AML cells [8]. Further
studies are warranted to show whether or not pre-treat-
ment of cytostatic drugs potentate synergistic effects in
Sorafenib treated ALL cells.
Additionally, we investigated antiproliferative effects of
Sorafenib in combination with RAD001, a mTOR inhibitor
to enhance toxicity in ALL cells. It has been shown, that
inhibition of the Ras/Raf/Mek/Erk and PI3K/Akt/mTOR
pathways is more effective and induces synergistically
effects [36,39]. Combination of Sorafenib with RAD001
was associated with a significant inhibition of ALL cell
growth. Previous studies demonstrated that RAD001
caused G1 cell cycle arrest and did not induce apoptosis in
different cancer cell lines [40-42]. Furthermore, it was
reported that combination of RAD001 with the new RAF
inhibitor LBT613 led to a significant decreased prolifera-
tion in glioblastoma cells [43]. Treatment with RAD001
and Sunitinib synergistically inhibited the proliferation of
leukemia cells [44]. A previous report by Tamburini et al.,
2008 demonstrated that RAD001 induced an up-regula-
tion of phosphorylated Akt levels in AML cells [45]. These
data suggest that rather a pre-treatment than concomitant
treatment with RAD001 may enhance Sorafenib antiproli-
ferative effects on ALL cells. However, additional studies
are needed to evaluate the efficacy of combination treat-
ments with Sorafenib and anticancer drugs in ALL.
Conclusion
This study shows that the multikinase inhibitor Sorafenib
blocks cell proliferation and induces apoptosis by clea-
vage of caspases 3, 7 and PARP in ALL cells. In addition,
we could demonstrate that Sorafenib significantly inhibits
Figure 5 Combination of Sorafenib with cytotoxic drugs inhibits cell proliferation and induces apoptosis and necrosis.S E Mc e l l sw e r e
treated both separately and in combination with Sorafenib (0.73 μM or 7.3 μM) and with cytarabine (250 nM) or doxorubicin (12.5 nM) or
RAD001 (1 nM or 10 nM) for 72 h. All drugs had effects on proliferation and rate of apoptosis and necrosis between treatment groups.
Statistically significant effects were detected in regards to proliferation between all combination treatments vs. DMSO control and in regards to
apoptosis between 7.3 μM Sorafenib and 12.5 nM doxorubicin vs. control (aadj = 0.006 for cytarbine and doxorubicine analyses; aadj = 0.003 for
RAD001 analyses). Results are displayed as mean +/- SD of three independent experiments.
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Page 9 of 11the PI3K/Akt/mTOR pathway, which might be an impor-
tant action mode besides the well known effects on the
Ras/Raf/Mek/Erk pathway. Given that Sorafenib displays
significant antileukemic activity in vitro,i tm i g h tb ea
potential drug for a target therapy approach in ALL.
Additional material
Additional file 1: Bliss analyses of Sorafenib and 2
nd Drug effects
on SEM cells. Analyses of synergism interaction effect of two mixed
substances (Sorafenib and a cytostatic) using Bliss additivism model for
effect classification into “synergistic"/"antagonistic"/"additive” is displayed.
The difference (delta) between a theoretical expected (white bar) and
the experimental measured (grey bar) inhibition effect of the mixture on
proliferation is > 0, reflecting a synergistic, above the expected Bliss-
"additive” in nature effect. Sorafenib demonstrates synergystic effects on
proliferation inhibition when combined with cytarabine, doxorubicin and
RAD001.
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